for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

SSY Group Ltd

2005.HK

Latest Trade

4.09HKD

Change

-0.04(-0.97%)

Volume

14,287,829

Today's Range

4.01

 - 

4.15

52 Week Range

3.82

 - 

8.29

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.13
Open
4.13
Volume
14,287,829
3M AVG Volume
278.78
Today's High
4.15
Today's Low
4.01
52 Week High
8.29
52 Week Low
3.82
Shares Out (MIL)
3,026.10
Market Cap (MIL)
12,376.75
Forward P/E
13.12
Dividend (Yield %)
2.44

Next Event

SSY Group Ltd Annual Shareholders Meeting

Latest Developments

More

SSY Group Says Dexmedetomidine Hydrochloride Has Obtained Approval For Registration From China's NMPA To Become A Bulk Drug

Ssy Group Obtained Approval For Drug Production And Registration For Dexmedetomidine Hydrochloride Injection From China's NMPA

Ssy Group Says Blonanserin Obtained Approval For Registration From China's NMPA

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About SSY Group Ltd

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Industry

Biotechnology & Drugs

Contact Info

Rooms 4902-03, 49th Floor, Central Plaza

18 Harbour Road

Wanchai

Hong Kong

+852.null.26880869

http://www.ssygroup.com.hk/

Executive Leadership

Jiguang Qu

Executive Chairman of the Board, Chief Executive Officer

Hing Yeung Chow

Chief Financial Officer, Executive Director, Company Secretary

Guo Meng

Executive Director

Xuejun Su

Executive Director

Hao Feng

Non-Executive Director

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2018

4.2K

2019

4.6K

2020

4.3K

2021(E)

5.8K
EPS (HKD)

2018

0.300

2019

0.373

2020

0.201

2021(E)

0.303
Price To Earnings (TTM)
19.39
Price To Sales (TTM)
2.52
Price To Book (MRQ)
2.12
Price To Cash Flow (TTM)
12.39
Total Debt To Equity (MRQ)
42.40
LT Debt To Equity (MRQ)
22.83
Return on Investment (TTM)
9.59
Return on Equity (TTM)
7.31

Latest News

Latest News

BRIEF-Ssy Group Says Turnover For Three Months Decreased By 7.6% To About Rmb855 Million

* SSY GROUP LTD - TURNOVER GROUP FOR THREE MONTHS DECREASED BY 7.6% TO ABOUT RMB855 MILLION

BRIEF-Ssy Group Posts FY Revenue Of Hk$4,636 Mln

* - FY NET PROFIT WAS HK$1,136 MILLION, UP 24.6% Source text for Eikon: Further company coverage:

BRIEF-SSY Group Gets Approval For Drug Production & Registration For Ropivacaine Hydrochloride Injection

* GOT APPROVAL FOR DRUG PRODUCTION & REGISTRATION FOR ROPIVACAINE HYDROCHLORIDE INJECTION IN FORM OF POLYPROPYLENE AMPOULE FROM NMPA Source text for Eikon: Further company coverage:

BRIEF-SSY Group Says ‍Unit Shijiazhuang No.4 Pharmaceutical Gets Second ​Shipping Order

* UNIT GOT 2ND SHIPPING ORDER FROM STATE'S CORONAVIRUS EPIDEMIC JOINT PREVENTION & JOINT CONTROL MECHANISM MEDICAL MATERIALS SAFEGUARD TEAM Source text for Eikon: Further company coverage:

BRIEF-SSY Group Says Unit To Supply 50,000 Boxes Of Abidol Hydrochloride Capsules In Batches To Hubei

* SSY GROUP - UNIT TO SUPPLY 50,000 BOXES OF ABIDOL HYDROCHLORIDE CAPSULES IN BATCHES TO HUBEI PROVINCE BY 26 FEB 2020

BRIEF-SSY Group Says Abidol, Ribavirin Included In "Diagnosis & Treatment Program For Coronavirus Infected Pneumonia" In PRC

* ABIDOL, RIBAVIRIN INCLUDED IN "DIAGNOSIS & TREATMENT PROGRAM FOR CORONAVIRUS INFECTED PNEUMONIA BY NATIONAL HEALTH COMMISSION OF PRC

BUZZ-Scisys: Jumps after CGI offers to buy co for 254.15p/share

** IT services developer Scisys' up 21.1% at 250p after Canadian IT and consultancy company CGI Inc makes all cash offer of 254.15p/share for SSY

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up